- Report
- November 2023
- 90 Pages
United States
From €3087EUR$3,500USD£2,672GBP
- Report
- September 2024
- 82 Pages
Japan
From €3087EUR$3,500USD£2,672GBP
- Report
- April 2023
- 86 Pages
Europe
From €3528EUR$4,000USD£3,054GBP
- Report
- April 2023
- 120 Pages
Global
From €4189EUR$4,750USD£3,626GBP
- Report
- June 2024
- 143 Pages
Global
From €2205EUR$2,500USD£1,909GBP
- Report
- April 2024
- 160 Pages
Global
From €4382EUR$4,969USD£3,794GBP
- Report
- August 2024
- 150 Pages
Global
From €2460EUR$2,789USD£2,129GBP
- Report
- February 2024
- 180 Pages
Global
From €4382EUR$4,969USD£3,794GBP
- Report
- June 2024
- 79 Pages
Global
From €3082EUR$3,495USD£2,668GBP
- Report
- June 2023
- 74 Pages
Global
From €3082EUR$3,495USD£2,668GBP
- Report
- September 2023
- 280 Pages
Global
€4229EUR$4,795USD£3,661GBP
- Report
- October 2022
- 204 Pages
Global
From €1764EUR$2,000USD£1,527GBP
- Report
- October 2022
- 94 Pages
Global
From €1764EUR$2,000USD£1,527GBP
- Report
- August 2024
- 89 Pages
Global
From €3500EUR$4,251USD£3,136GBP
Sarcoma is a type of cancer that affects the connective tissues of the body, such as muscle, bone, fat, and blood vessels. Sarcoma drugs are used to treat this type of cancer, and are part of the larger oncology drug market. These drugs are typically used in combination with other treatments, such as surgery, radiation, and chemotherapy. Sarcoma drugs are designed to target the specific type of cancer, and can be used to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of metastasis.
The sarcoma drug market is highly competitive, with many companies developing new treatments and therapies. Some of the major players in the market include Pfizer, Merck, Novartis, Bristol-Myers Squibb, and Eli Lilly. Other companies, such as Amgen, AstraZeneca, and Celgene, are also developing treatments for sarcoma. Show Less Read more
